High BMI at MS diagnosis tied to faster disability progression: Study
Having a higher body mass index (BMI), a measure of body fat based on a person’s height and weight,…
Articles by Andrea Lobo, PhD
CAR-M cell therapy shows promise in preclinical studies
Liberate Bio’s CAR-M cell therapy almost completely depleted B-cells in nonhuman primates, suggesting the approach may be used to…
Headaches more frequent, more severe in people with MS: Study
People with multiple sclerosis (MS) are more than twice as likely to experience headaches, including migraines, than their healthy counterparts,…
Octave wins grant to develop blood test for measuring MS progression
A new grant from the Valhalla Foundation will help Octave Bioscience advance the development of a biomarker blood…
ECTRIMS 2025: NMSS funding, support drives progress in care
The world’s largest meeting on multiple sclerosis (MS) has wrapped up for the year, and the National Multiple…
ECTRIMS 2025: Vidofludimus calcium shows promise against MS
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people…
ECTRIMS 2025: Ocrevus as good as Gilenya for treating MS in children
Children and adolescents living with multiple sclerosis (MS) seem to benefit at least as much — and for some…
ECTRIMS 2025: Frexalimab shows long-term benefits for MS patients
Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease…
ECTRIMS 2025: Ultra-processed foods may fuel disease in early MS
Consuming large amounts of ultra-processed foods (UPF) — products high in additives, artificial ingredients, and extensive processing — is associated…
ECTRIMS 2025: High-dose Vitamin D reduces MS activity, study finds
Increasing blood vitamin D levels with high-dose supplementation can significantly reduce the risk of new disease activity in people…
ECTRIMS 2025: Cognitive changes may precede physical decline
People with multiple sclerosis (MS) seem to experience significant changes in cognition more than a year before significant physical…
ECTRIMS 2025: A ‘new era’ for diagnosis and treatment
The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the world’s largest congress…
Emergency visits climb long before symptom onset in pediatric MS
Children and adolescents who go on to develop multiple sclerosis (MS) begin visiting the emergency department more often than…
Phase 3 trial begins for at-home injectable version of Briumvi
TG Therapeutics has started enrolling participants in a Phase 3 trial to test a new version of Briumvi…
Health Canada warns of severe allergy risk with some MS products
Health Canada is warning that glatiramer acetate products, used in the country to treat relapsing-remitting multiple sclerosis (MS), may cause…
Tolebrutinib gets UAE OK for progressive MS, a world 1st
The United Arab Emirates became the first country to approve tolebrutinib, clearing it to treat adults with nonrelapsing…
Civicascript says its generic version of Ampyra offers major savings
A generic version of Ampyra (dalfampridine), used to improve walking in adults with multiple sclerosis (MS), is now…
Study finds better physical ability is tied to higher cognition in MS
Having better physical performance is associated with higher cognitive function in people with multiple sclerosis (MS), particularly among those…
Switching to Ocrevus or Kesimpta doesn’t alter either’s effectiveness
Switching between CD20-targeting antibodies Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) doesn’t affect either’s effectiveness at lowering disease activity and…
Fatigue, cognition in MS patients aren’t barriers to healthy habits
Three self-reported prevalent symptoms among people with multiple sclerosis (MS) – fatigue, mobility issues, and cognitive impairment – are…
MS Australia funds project that explores EBV, MS genetic risk link
A research project to explore the genetic connection between the Epstein-Barr virus (EBV) and the risk of developing multiple…
Stem cell transplant may slow RRMS disease progression: Study
Autologous hematopoietic stem cell transplant (aHSCT) could slow disease progression in people with relapsing-remitting multiple sclerosis (RRMS), according to…
DMTs before, during MS pregnancy generally safe: Registry data
About 62% of multiple sclerosis (MS) patients use disease-modifying therapies (DMTs) before and during pregnancy, and the medications…
Number of visits to MS clinics not tied to mortality risk in disease
A person’s total number of visits to multiple sclerosis (MS) clinics is not associated with a lower risk of…
GFAP protein may help predict MS severity, response to treatment
Blood levels of a protein called GFAP, which reflects the activation and damage to support cells in the brain and…
Mitochondrial problems linked to loss of motor control cells in MS
Mitochondrial abnormalities, or problems in the powerhouses of cells, seem to be a main contributor to the death of important…
Foralumab nasal spray trial starts dosing patients at Weill Cornell
A multicenter Phase 2a clinical trial testing foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) has…
Aetna agrees to reimburse PoNS device for MS patients
Aetna Healthcare has agreed to reimburse Helius Medical Technologies’ PoNS device, short for Portable Neuromodulation Stimulator, which uses electrical…
4 Canadian MS nurses among 11 honored for excellence in care
Four Canadian nurses are among the 11 recipients of this year’s International Nightingale Awards, which support innovative projects aimed…
Real-world data support use of Ocrevus in children, teens with MS
Ocrevus (ocrelizumab) appears to be safe and effective for children and adolescents with multiple sclerosis (MS), according to…